+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Eribulin"

Triple Negative Breast Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Triple Negative Breast Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Eribulin is a chemotherapy drug used to treat metastatic breast cancer. It is a microtubule inhibitor, meaning it works by blocking the growth of cancer cells. It is typically used in combination with other drugs, such as trastuzumab, to treat advanced or metastatic breast cancer. Eribulin is approved by the US Food and Drug Administration (FDA) for the treatment of metastatic breast cancer in patients who have already received at least two other chemotherapy regimens. Eribulin is marketed by Eisai Inc. in the United States and by other companies in other countries. It is available in both tablet and injection form. The drug is also available in generic form in some countries. Companies in the Eribulin market include Eisai Inc., Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more